Description

Selegiline Hydrochloride, USP

Selegiline Hydrochloride, USP is a high-purity, pharmaceutical-grade monoamine oxidase B (MAO-B) inhibitor used in oral and transdermal formulations for the treatment of Parkinson’s disease and major depressive disorder (MDD). By selectively inhibiting MAO-B at therapeutic doses, Selegiline prolongs dopaminergic activity in the central nervous system and enhances neurochemical balance. Selegiline HCl

• Is a USP-compliant MAO-B inhibitor active pharmaceutical ingredient (API)
• Enhances central dopamine levels via irreversible MAO-B inhibition
• Is indicated for Parkinson’s disease and adjunctive therapy in depression
• Is suitable for oral tablets, capsules, orally disintegrating tablets (ODTs), and transdermal patches

Chemically known as (R)-(-)-N,α-Dimethyl-N-2-propynylphenethylamine hydrochloride, Selegiline HCl acts as an irreversible MAO-B inhibitor, thereby preventing the breakdown of Dopamine and other monoamines in the brain. At lower doses, it is highly selective for MAO-B; however, transdermal or higher systemic exposures may inhibit both MAO-A and B, offering broader neurochemical modulation.

In pharmaceutical development, Selegiline Hydrochloride, USP is used in:

• Parkinson’s disease management, particularly in early stages, to reduce motor symptoms and delay the need for levodopa
• Adjunctive therapy for major depressive disorder, particularly via transdermal delivery to bypass first-pass metabolism and reduce tyramine-related dietary restrictions
• Oral disintegrating tablets (ODTs) and capsules for improved patient compliance and rapid CNS delivery
• Transdermal systems for sustained delivery and improved pharmacokinetics

CarboMer supplies Selegiline Hydrochloride, USP with tight control over residual solvents, impurities, and chiral purity. The product complies fully with the U.S. Pharmacopeia (USP) monograph and is manufactured under GMP-controlled conditions to ensure consistency, safety, and reproducibility in regulated pharmaceutical environments.

The API is packaged in sealed, tamper-evident, light- and moisture-resistant containers. Available in R&D, pilot, and commercial quantities. Minimum order quantities (MOQ), lead times, and full documentation—including CoA and SDS are available to support regulatory submissions and commercial readiness.

Each batch undergoes full pharmacopeial -compliant testing, including identity, assay, optical rotation, related substances, and microbiological purity. Chiral integrity is confirmed via validated analytical methods such as HPLC.

As with all CarboMer APIs, Selegiline Hydrochloride, USP is backed by formulation guidance, regulatory support, and technical expertise to accelerate the development of targeted neurologic and psychiatric therapies.